Real‐World Experience With Plasma PTAU217 as a Screening Tool of Patients at Risk of Alzheimer's Disease in a Memory Clinic
Plasma pTau217 exhibits better results than plasma pTau181 in the preclinical stages of AD continuum. All results together suggest that plasma pTau217 is robust enough to be implemented as a screening tool of AD risk in the memory clinics. However, since plasma biomarkers are not still approved by the international guidelines for their use in the clinical practice, a CSF/PET confirmatory test is mandatory required. Further studies are needed to obtain more clinical data and improve the biomarker's performance to finally substitute CSF/PET biomarkers as diagnostic tests.
Authors
- Laura Montrreal (ORCID: https://orcid.org/0000-0002-0010-645X)
- Adelina Orellana (ORCID: https://orcid.org/0000-0002-0204-1944)
- Montserrat Alegret (ORCID: https://orcid.org/0000-0002-8164-9500)
- C. Olive (ORCID: https://orcid.org/0000-0001-6682-4502)
- Pablo García‐González (ORCID: https://orcid.org/0000-0003-0125-5403)
- Pilar Sánz
- Victoria M. Fernandez
- Marta Marquié
- María Luisa Sarrate Capdevila
- Natalia Tatinya
- Raquel Puerta
- Sergi Valero
- Itziar de Rojas
- Marta Martinez
- Mercè Boada
- Amanda Cano
- Agustin Ruiz
- Álvaro Muñoz‐Morales
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Universitat Internacional de Catalunya (ES)
- Fundació ACE (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_101897
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00